TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Changes in MRI biomarkers of endothelial dysfunction: cerebral vascular reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in MRI biomarkers of endothelial dysfunction: femoral artery flow-mediated dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in MRI biomarkers of endothelial dysfunction: venous oxygen saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in MRI biomarkers of endothelial dysfunction: blood flow velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Quantitative clinician-reported usability measure of ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient comfort measures during ultrasound-guided injection
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Time to complete superior laryngeal nerve injection under ultrasound
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious AEs
Endpoint domain: Adverse events/effects
Primary endpoint: Objective Response Rate - Percentage of Participants With Objective Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Successfully Analyzed EEG Recordings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects Completing the Entire Study Protocol Through the Follow-up Phase
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Number of Subjects Withdrawn From Protocol Due to Adverse Events or Participation Burden
Endpoint domain: Adverse events/effects
Primary endpoint: Mean change in IIEF-EF scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anal sphincter function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Rate of patients who decide to join in a clinical trial
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of hepatic encephalopathy patients who remain in clinical trial until completion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Waist Hip Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SF-36 Quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Body weight loss in Kg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Longitudinal changes in alemtuzumab ADAs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in student mental health symptoms from Baseline to Post Intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concomitant medications
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of dhAM + SOC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bristol Rheumatoid Arthritis Fatigue Multidimensional Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Cost-effectiveness of routine screening
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Acceptability of educational materials
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in opioid related knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Flicking Distance Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Six-minute walk test (6MWT) distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to First Tachycardia Episode
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Progression Free Survival at 48 weeks
Endpoint domain: Mortality/survival
Primary endpoint: Occurrence of a Grade ≥3 adverse event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of participants with plasma HIV-1 RNA <200 copies/mL 8 weeks after interruption of ART
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in elbow extension range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline Global Cognition
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change From Baseline Functional Task Performance and Activity Participation
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change From Baseline Psychosocial Function (Depression)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cumulative time outside recommended BIS levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Periods outside recommended BIS levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Soft Tissue to Bone Healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommended Phase 2 dose (RP2D)
Endpoint domain: Resource use
Primary endpoint: RECIST v1.1 objective response rate (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Prostate specific antigen (PSA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Arrest of the carious lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of knee pain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Daily self-reported mood instability
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of Participants who Adhere to 100% of Study Procedures
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Angle difference between x-ray and CT scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Motor functions
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: recurrence of the lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: breast cosmetic outcome
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Adverse events after injection of 68Ga-FAPI-FS
Endpoint domain: Adverse events/effects
Primary endpoint: Pain Disability Index (PDI-D)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of remembered items
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Strength of functional connectivity between frontal and parietal cortex in theta-frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Participant Satisfaction with the Biobehavioral Intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Profile of Mood States for the Biobehavioral Intervention
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Efficacy of SOLACEA-H vs HYDROLINK-NVU
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRT Feasibility
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: MRT Acceptability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Scalp Health- Erythema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Scalp Health- ASFS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Scalp Health- Folliculitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Hair Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Venous oxygen saturation measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subcutaneous infusion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early identification of metastases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in sleep onset latency (SOL)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Functional Recovery Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Postoperative Recovery Profile
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Antibody levels for anti-pertussis and anti-diphtheria, tetanus, HIB, and poliomyelitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Neuropeptide Y expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Information Processing Speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Patients Achieving Guideline-recommended Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Intracranial Pressure Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Adult ADHD Self-Report Scale (ASRS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Clinical Global Impressions-Severity (CGI-S)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Orbital complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of analyzable samples collected
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: working memory skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resting state EEG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: task-based EEG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Erythrocyte Sedimentation Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alanine Transaminase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aspartate Transaminase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alkaline Phosphatase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Headache impact
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduce percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Range of Motion of Cervical and Thoracic Regions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Participants Achieving MRD Negative Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in spherical equivalent (SE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: State Trait Anxiety Index - Y version
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Upper limb spasticity development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Binge Eating Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of clinically significant radiation dermatitis
Endpoint domain: Adverse events/effects
Primary endpoint: Compliance with ERAS protocol criteria
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Total relative peripheral refraction from MRT (D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional alteration of left ventricle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Smoking per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Desired degree of quitting
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Craving rating (cue)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Presence of cholelithiasis in umbilical hernia patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Presence of umbilical hernia in cholelithiasis patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Wrist Joint Position Sense
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Hand Performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Pinch Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in Self-reported Hand Functions
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: quantitative dosage of auto-Abs against type I IFNs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: neutralization capacity evaluation of auto-Abs against type I IFNs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time to first occurrence of major adverse cardiovascular event (MACE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean change in the ItchRO(Obs) severity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in cartilage thickness of the medial compartment of the knee
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Findings of ovary tissue specimens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Students' self-efficacy scores for applications
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Student's satisfaction with the education provided
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Self-confidence scale scores in learning
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change of Craving
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Severe respiratory insufficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Lip size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage reduction in symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment success at one year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time-related incidence of adverse events and death
Endpoint domain: Adverse events/effects
Primary endpoint: Evaluation of Mean Pressure Gradient (mmHg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in heart failure status based on NYHA functional classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Feasibility and usability of device
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Reliability of Anchorage for Sound Processor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depressive Symptom Scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: tear break up time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: corneal surface staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge of COVID-19 prevention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: COVID-19 vaccination rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of adequate medication adherence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving a Static Physician's Global Assessment (sPGA) of Clear (0) or Almost Clear (1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of Participants Achieving ≥75% Improvement from Baseline in Psoriasis Area and Severity Index (PASI) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Survival free of disabling stroke
Endpoint domain: Mortality/survival
Primary endpoint: Peak Plantar Force (total foot)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PROMIS Patient Reported Outcomes for Physical Function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of Participants Experiencing Cytokine Release Syndrome (CRS) Events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Experiencing Immune Cell-Associated Neurotoxicity Syndrome (ICANS) Events
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Observed Concentration (Cmax) of ABBV-383
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in levels of cerebrospinal fluid heparan sulfate from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the raw scores of cognitive testing measured from baseline (BSID-III)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Rate of accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of episode (DOE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postpartum Specific Anxiety Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change From Baseline to Month 6 in MDS-UPDRS Part II (OFF-state)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Differentiation of stroke from non-stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cmax: Maximum Observed Serum Concentration of Lu AG13909
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-infinity: Area under the plasma concentration curve of x from zero to infinity of Lu AG13909
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants converting to Transfusion Dependence
Endpoint domain: Mortality/survival
Primary endpoint: Histopathologic diagnosis of chorionic villi
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunohistochemistry staining
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Shivering
Endpoint domain: Adverse events/effects
Primary endpoint: Diabetes self-management skills
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in the Progressive Supranuclear Palsy Rating Scale (PSP-RS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in clinical global impression (CGI) scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Montgomery-Åsberg Depression Rating Scale (MADRS) scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: FAPI positivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protective Levels of PrEP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Six Minute Walk Test-Distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean distress evaluated by parents
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline in Vaccinia virus specific plaque reduction neutralizing antibody (PRNT) Geometric Mean Titers (GMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Occurrence of Medically Attended Adverse Events (MAAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants with Drug Related Serious Infections
Endpoint domain: Adverse events/effects
Primary endpoint: Retention in HIV Services
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Body Dissatisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Accuracy of prehospital stroke diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Recommended Phase II dose (RP2D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Increase of motor scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inpatient safety
Endpoint domain: Adverse events/effects
Primary endpoint: Dizziness Visual Analog Scale (DVAS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Plasma iron availability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Integrated area under the curve (iAUC) for plasma glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Minimal residual disease (MRD)-negativity rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of death or unacceptable adverse event
Endpoint domain: Mortality/survival
Primary endpoint: Natural history of ONB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Berg Balance Scale score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients achieving steroid-free clinical remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes